AI Summary
The article discusses the findings of a phase 2 trial on the Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen, with a focus on the secondary and exploratory outcomes. The results show that the regimen and booster dose were well tolerated, and both participants who were boosted 1 year and 2 years after the initial dose exhibited a strong humoral immune response. This suggests that the regimen is effective and that the booster dose can be administered flexibly, supporting prophylactic vaccination in at-risk populations.
Overall, the vaccine regimen and booster dose were well tolerated. A similar and robust humoral immune response was observed for participants boosted 1 year and 2 years after the first dose, supporting the use of the regimen and flexibility of booster dose administration for prophylactic vaccination in at-risk populations.